Compare NBTX & EPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | EPAC |
|---|---|---|
| Founded | 2003 | 1910 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2018 | 1994 |
| Metric | NBTX | EPAC |
|---|---|---|
| Price | $29.31 | $35.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $54.00 | $48.00 |
| AVG Volume (30 Days) | 137.8K | ★ 329.5K |
| Earning Date | 09-24-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.11% |
| EPS Growth | N/A | ★ 8.97 |
| EPS | N/A | ★ 1.24 |
| Revenue | N/A | ★ $616,899,000.00 |
| Revenue This Year | N/A | $3.69 |
| Revenue Next Year | $50.69 | $4.91 |
| P/E Ratio | ★ N/A | $28.62 |
| Revenue Growth | N/A | ★ 4.65 |
| 52 Week Low | $14.78 | $32.35 |
| 52 Week High | $57.14 | $43.97 |
| Indicator | NBTX | EPAC |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 53.01 |
| Support Level | $20.18 | $34.24 |
| Resistance Level | $35.38 | $36.54 |
| Average True Range (ATR) | 1.55 | 0.83 |
| MACD | 0.84 | 0.09 |
| Stochastic Oscillator | 92.73 | 66.11 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.